Explore

Trendline Trendline
Janux Therapeutics Reports Q1 2026 Financial Results and Pipeline Progress

Janux Therapeutics Reports Q1 2026 Financial Results and Pipeline Progress

Janux Therapeutics Reports Q1 2026 Financial Results and Pipeline Progress
Trendline Trendline
Janux Therapeutics Reports Q1 2026 Financial Results and Strategic Developments

Janux Therapeutics Reports Q1 2026 Financial Results and Strategic Developments

Janux Therapeutics Reports Q1 2026 Financial Results and Strategic Developments
Trendline Trendline
Vir Biotechnology Reports Strong Financial Position and Advances in Cancer and Hepatitis Delta Programs

Vir Biotechnology Reports Strong Financial Position and Advances in Cancer and Hepatitis Delta Programs

Vir Biotechnology Reports Strong Financial Position and Advances in Cancer and Hepatitis Delta Programs
Trendline Trendline
Verastem Oncology Reports $18.7 Million Revenue in Q1 2026 Amid New Clinical Trials

Verastem Oncology Reports $18.7 Million Revenue in Q1 2026 Amid New Clinical Trials

Verastem Oncology Reports $18.7 Million Revenue in Q1 2026 Amid New Clinical Trials
Trendline Trendline
Verastem Oncology Reports Financial Results and Initiates New Cancer Trials

Verastem Oncology Reports Financial Results and Initiates New Cancer Trials

Verastem Oncology Reports Financial Results and Initiates New Cancer Trials
Trendline Trendline
AN2 Therapeutics to Engage in 2026 Stifel Virtual Targeted Oncology Forum

AN2 Therapeutics to Engage in 2026 Stifel Virtual Targeted Oncology Forum

AN2 Therapeutics to Engage in 2026 Stifel Virtual Targeted Oncology Forum
Trendline Trendline
Diakonos Oncology Receives FDA Fast Track Designation for Melanoma Treatment

Diakonos Oncology Receives FDA Fast Track Designation for Melanoma Treatment

Diakonos Oncology Receives FDA Fast Track Designation for Melanoma Treatment
Trendline Trendline
Generate Biomedicines Reports Q1 2026 Financial Results Amid Clinical Advancements

Generate Biomedicines Reports Q1 2026 Financial Results Amid Clinical Advancements

Generate Biomedicines Reports Q1 2026 Financial Results Amid Clinical Advancements
Trendline Trendline
TORL BioTherapeutics Appoints Aran Maree as CEO to Lead Next Growth Phase

TORL BioTherapeutics Appoints Aran Maree as CEO to Lead Next Growth Phase

TORL BioTherapeutics Appoints Aran Maree as CEO to Lead Next Growth Phase
Trendline Trendline
LTZ Therapeutics Secures $38 Million to Advance Immunotherapy Pipeline

LTZ Therapeutics Secures $38 Million to Advance Immunotherapy Pipeline

LTZ Therapeutics Secures $38 Million to Advance Immunotherapy Pipeline
Trendline Trendline
Nuvectis Pharma Reports Increased Net Loss in Q1 2026

Nuvectis Pharma Reports Increased Net Loss in Q1 2026

Nuvectis Pharma Reports Increased Net Loss in Q1 2026
Trendline Trendline
NImmune Biopharma Presents Promising Data for IBD Treatment at Digestive Disease Week

NImmune Biopharma Presents Promising Data for IBD Treatment at Digestive Disease Week

NImmune Biopharma Presents Promising Data for IBD Treatment at Digestive Disease Week